On the other hand, aging and aging-related disorders are associated with reduced PGC1-α function, may be associated with reduced ACOX1 activity, lowered SPM levels, and delayed resolution of inflammation and may be improved by strategies rising ACOX1 (metabolic syndrome and diabetes) and SPM (brain and eye aging along with corresponding neurodegenerative disorders, atherosclerosis, and stroke). This evidence concerns the gene PPARGC1A and stroke disorder.